Direkt zum Inhalt
Merck

Prevalence of Bordetella infection in a hospital setting in niamey, niger.

Journal of tropical pediatrics (2014-02-18)
Viviane Jusot, Said Aberrane, Franck Alé, Boubou Laouali, Issa Moussa, Sanda A Alio, Eric Adehossi, Jean-Marc Collard, Rebecca F Grais
ZUSAMMENFASSUNG

Bordetella pertussis still poses an important health threat in developing countries. In Niger, notified pertussis cases are few despite the low diphtheria-tetanus-pertussis/pentavalent vaccine coverage. We aimed to estimate the prevalence of B. pertussis in children aged <5 years consulting at a pediatric ward. A 5-month study in 2011 recruited 342 children with respiratory symptoms at the National Hospital of Niamey. Nasopharyngeal aspirates were tested by culture and real-time polymerase chain reaction. Overall, 34 (11.2%) of the 305 available nasopharyngeal aspirates tested by real-time polymerase chain reaction were positive for a Bordetella spp., with an estimated prevalence of 8.2 cases per 1000 children aged <5. None was notified to the surveillance network. A single specimen was positive on culture. This study, the first to provide laboratory-confirmed data on pertussis in Niger, highlights the need to sensitize health care personnel to actively notify clinical cases and to integrate laboratory diagnosis in the existing surveillance system.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

USP
Cephalexin, United States Pharmacopeia (USP) Reference Standard
Supelco
Cefalexin, VETRANAL®, analytical standard